Pharsight

Vonjo is owned by Cti Biopharma Corp.

Vonjo contains Pacritinib Citrate.

Vonjo has a total of 3 drug patents out of which 0 drug patents have expired.

Vonjo was authorised for market use on 28 February, 2022.

Vonjo is available in capsule;oral dosage forms.

Vonjo can be used as use of pacritinib for inhibiting janus associated kinase 2(jak2); treatment of myelofibrosis with pacritinib, treatment of myelofibrosis with pacritinib; use of pacritinib for inhibiting janus associated kinase 2(jak2).

Drug patent challenges can be filed against Vonjo from 2026-02-28.

The generics of Vonjo are possible to be released after 25 March, 2030.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8153632	CTI BIOPHARMA CORP	Oxygen linked pyrimidine derivatives	Jan, 2029 (5 years from now)
US8980873	CTI BIOPHARMA CORP	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt	Mar, 2030 (6 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9573964	CTI BIOPHARMA CORP	Oxygen linked pyrimidine derivatives	May, 2028 (4 years from now)